BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18768834)

  • 1. Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.
    Björck P; Beilhack A; Herman EI; Negrin RS; Engleman EG
    J Immunol; 2008 Sep; 181(6):3811-7. PubMed ID: 18768834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
    del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
    J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
    Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
    Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
    Pooley JL; Heath WR; Shortman K
    J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
    Schuurhuis DH; van Montfoort N; Ioan-Facsinay A; Jiawan R; Camps M; Nouta J; Melief CJ; Verbeek JS; Ossendorp F
    J Immunol; 2006 Apr; 176(8):4573-80. PubMed ID: 16585547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.
    Ontiveros F; Wilson EB; Livingstone AM
    Immunology; 2011 Apr; 132(4):549-58. PubMed ID: 21255009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma expressed by T cells regulates the persistence of antigen presentation by limiting the survival of dendritic cells.
    Russell MS; Dudani R; Krishnan L; Sad S
    J Immunol; 2009 Dec; 183(12):7710-8. PubMed ID: 19923462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells.
    Oran AE; Robinson HL
    J Immunol; 2003 Aug; 171(4):1999-2005. PubMed ID: 12902504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
    Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
    Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitated antigen uptake and timed exposure to TLR ligands dictate the antigen-presenting potential of plasmacytoid DCs.
    Kool M; Geurtsvankessel C; Muskens F; Madeira FB; van Nimwegen M; Kuipers H; Thielemans K; Hoogsteden HC; Hammad H; Lambrecht BN
    J Leukoc Biol; 2011 Dec; 90(6):1177-90. PubMed ID: 21934071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo.
    Ignatius R; Mahnke K; Rivera M; Hong K; Isdell F; Steinman RM; Pope M; Stamatatos L
    Blood; 2000 Nov; 96(10):3505-13. PubMed ID: 11071648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW; Ratner DM; Seeberger PH; Hacohen N
    Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.
    Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C
    J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of mucosal adjuvants on antigen passage and CD4+ T cell activation during the primary response to airborne allergen.
    Wikstrom ME; Batanero E; Smith M; Thomas JA; von Garnier C; Holt PG; Stumbles PA
    J Immunol; 2006 Jul; 177(2):913-24. PubMed ID: 16818746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.